Indian Drug Major Sun Pharma To Sell Its Manufacturing Facility In Ireland

Sun Pharmaceutical Industries plans to sell a manufacturing facility in Ireland that was owned by Ranbaxy, which has been acquired by the Indian drug major.

The divestment comes on the heels of Sun Pharma Managing Director Dilip Shanghvi saying in August that the company would look at rationalizing manufacturing footprint." decisions are being made to either close or divest some of our manufacturing facilities. Currently, the Ireland facility has been identified for divestment," Sun Pharma spokesperson said.

Cambridge-Based Company Signs a $60 million Deal For a Drug With Mitsubishi Pharma
Biogen aims to access potential of MT-1303 in multiple sclerosis (MS), ulcerative colitis, Crohn’s disease, and other autoimmune diseases.

"In March this year, Sun Pharma successfully completed the merger of Ranbaxy. This has provided an opportunity to optimize overall manufacturing network in terms of capacity, costs and efficiencies," the spokesperson added.

The company completed the USD 4 billion acquisition of Ranbaxy in March, almost a year after announcing the deal.

Source-PTI

Mumbai-Based Drug Firm Gets USFDA Approval For Acne Treatment Medicine
Sun Pharma’s XiminoTM capsules are indicated for inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years and above.

Swiss Drug Firm Collaborates With Amgen to Develop Treatments for Alzheimer's Disease
Novartis and California-based biotech company Amgen will jointly develop neuroscience treatments for illnesses like Alzheimer's disease and migraine headaches.

Ahmedabad- based Drug Firm Takes Hold of 50-Year-Old Zyg Pharma Ltd
The acquisition will help Torrent Pharmaceuticals strengthen its position in the niche dermatological segment of the developed markets.